Stevanato Group (NYSE:STVN) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Stevanato Group S.p.A. (NYSE:STVN) saw strong trading volume on Wednesday. Approximately 625,050 shares were traded during trading, an increase of 21% from the average daily volume of 516,235 shares. The stock last traded at €13.69 and had previously closed at €14.10.

Stevanato Group News Roundup

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Third-quarter revenue rose 8% to €326.1 million, and Zacks reported that quarterly earnings and revenue exceeded consensus estimates. A separate valuation analysis argued STVN could be about 42% undervalued, offering a more positive view of the stock’s potential. Stevanato Group Q3 results Zacks Q3 estimates Undervaluation analysis
• Negative Sentiment: Management expects only low-single-digit growth in 2027, with lower GLP-1 syringe volumes linked to one customer. The outlook may be overshadowing the quarter’s revenue growth and raising concerns about customer concentration and near-term growth. 2027 outlook and GLP-1 demand
• Negative Sentiment: Law firms announced investigations into whether Stevanato’s disclosures met securities-law requirements, following the share-price decline and concerns about GLP-1-related disclosures. These are investigations, not findings of wrongdoing, but could add uncertainty for investors. Kehoe Law investigation notice Legal investigation coverage

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. UBS Group began coverage on shares of Stevanato Group in a report on Wednesday, September 9th. They set a “neutral” rating and a $23.00 target price on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on Stevanato Group in a report on Wednesday, October 7th. They set a “hold” rating on the stock. Weiss Ratings upgraded Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Finally, William Blair downgraded Stevanato Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Stevanato Group Stock Down 10.7%

The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.08 and a current ratio of 1.61. The stock’s 50 day moving average price is €20.35 and its 200-day moving average price is €18.11. The company has a market cap of $3.81 billion, a PE ratio of 22.70, a PEG ratio of 1.62 and a beta of 0.80.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported €0.16 EPS for the quarter, missing analysts’ consensus estimates of €0.17 by (€0.01). The firm had revenue of €326.06 million for the quarter. Stevanato Group had a net margin of 10.99% and a return on equity of 10.43%. On average, analysts predict that Stevanato Group S.p.A. will post 0.69 earnings per share for the current year.

Insider Buying and Selling at Stevanato Group

In other news, Director Luciano Santel sold 2,023 shares of Stevanato Group stock in a transaction dated Friday, August 7th. The stock was sold at an average price of €20.09, for a total value of €40,642.07. Following the completion of the transaction, the director owned 4,739 shares of the company’s stock, valued at €95,206.51. The trade was a 29.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Elisabetta Magistretti sold 2,045 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of €20.09, for a total transaction of €41,084.05. Following the sale, the director directly owned 2,930 shares of the company’s stock, valued at €58,863.70. This trade represents a 41.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 21,926 shares of company stock valued at $459,738 over the last ninety days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STVN. State of Wyoming purchased a new position in shares of Stevanato Group during the third quarter valued at about $75,000. Schwartz Investment Counsel Inc. raised its holdings in shares of Stevanato Group by 15.0% during the 3rd quarter. Schwartz Investment Counsel Inc. now owns 661,136 shares of the company’s stock worth $13,871,000 after acquiring an additional 86,385 shares in the last quarter. PineStone Asset Management Inc. grew its holdings in shares of Stevanato Group by 8.4% in the third quarter. PineStone Asset Management Inc. now owns 41,335 shares of the company’s stock valued at $867,000 after purchasing an additional 3,200 shares in the last quarter. Fenimore Asset Management Inc bought a new stake in Stevanato Group in the third quarter worth $12,212,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Stevanato Group during the second quarter valued at $59,000.

About Stevanato Group

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.